ACE2 and COVID-19: In 2020, Wrapp et al. proposed that COVID-19 led to lung damage and failure as a result of its binding to angiotensin-converting enzyme 2 (ACE2) in pulmonary alveoli via their superficial spike proteins and consequently, lower levels of ACE2 will be obtained [6].